nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—Protein Kinase Inhibitors—Nilotinib—hematologic cancer	0.414	1	CiPCiCtD
Ruxolitinib—JAK1—hematologic cancer	0.0971	0.379	CbGaD
Ruxolitinib—JAK3—hematologic cancer	0.0826	0.323	CbGaD
Ruxolitinib—RET—hematologic cancer	0.0403	0.158	CbGaD
Ruxolitinib—JAK2—Dasatinib—hematologic cancer	0.0373	0.27	CbGbCtD
Ruxolitinib—JAK2—hematologic cancer	0.0359	0.14	CbGaD
Ruxolitinib—MAP3K3—Dasatinib—hematologic cancer	0.0312	0.226	CbGbCtD
Ruxolitinib—MAP3K2—Dasatinib—hematologic cancer	0.027	0.195	CbGbCtD
Ruxolitinib—MAP3K19—Dasatinib—hematologic cancer	0.0179	0.13	CbGbCtD
Ruxolitinib—BMPR2—ovarian follicle—hematologic cancer	0.00255	0.0608	CbGeAlD
Ruxolitinib—CYP3A4—Bexarotene—hematologic cancer	0.00212	0.0154	CbGbCtD
Ruxolitinib—CYP3A4—Busulfan—hematologic cancer	0.00197	0.0143	CbGbCtD
Ruxolitinib—CYP3A4—Lomustine—hematologic cancer	0.00197	0.0143	CbGbCtD
Ruxolitinib—CYP3A4—Thiotepa—hematologic cancer	0.00176	0.0127	CbGbCtD
Ruxolitinib—CYP3A4—Methoxsalen—hematologic cancer	0.00137	0.00989	CbGbCtD
Ruxolitinib—CYP3A4—Bortezomib—hematologic cancer	0.0013	0.00941	CbGbCtD
Ruxolitinib—CYP3A4—Daunorubicin—hematologic cancer	0.00124	0.009	CbGbCtD
Ruxolitinib—CYP3A4—Cytarabine—hematologic cancer	0.0011	0.00794	CbGbCtD
Ruxolitinib—CYP3A4—Teniposide—hematologic cancer	0.00108	0.00782	CbGbCtD
Ruxolitinib—CYP3A4—Ifosfamide—hematologic cancer	0.000996	0.00722	CbGbCtD
Ruxolitinib—CYP3A4—Imatinib—hematologic cancer	0.000951	0.00689	CbGbCtD
Ruxolitinib—CYP3A4—Nilotinib—hematologic cancer	0.000864	0.00626	CbGbCtD
Ruxolitinib—CYP3A4—Vinorelbine—hematologic cancer	0.000857	0.00621	CbGbCtD
Ruxolitinib—CYP3A4—Triamcinolone—hematologic cancer	0.000784	0.00568	CbGbCtD
Ruxolitinib—CYP3A4—Dasatinib—hematologic cancer	0.000764	0.00554	CbGbCtD
Ruxolitinib—CYP3A4—Mitoxantrone—hematologic cancer	0.000755	0.00547	CbGbCtD
Ruxolitinib—CYP3A4—Betamethasone—hematologic cancer	0.000673	0.00487	CbGbCtD
Ruxolitinib—CYP3A4—Prednisolone—hematologic cancer	0.000664	0.00481	CbGbCtD
Ruxolitinib—CYP3A4—Prednisone—hematologic cancer	0.000627	0.00454	CbGbCtD
Ruxolitinib—CYP3A4—Irinotecan—hematologic cancer	0.000594	0.00431	CbGbCtD
Ruxolitinib—PLK1—hematopoietic system—hematologic cancer	0.000575	0.0137	CbGeAlD
Ruxolitinib—DCLK3—hematopoietic system—hematologic cancer	0.000545	0.013	CbGeAlD
Ruxolitinib—CYP3A4—Vinblastine—hematologic cancer	0.000528	0.00383	CbGbCtD
Ruxolitinib—CYP3A4—Vincristine—hematologic cancer	0.000519	0.00376	CbGbCtD
Ruxolitinib—CYP3A4—Etoposide—hematologic cancer	0.000476	0.00345	CbGbCtD
Ruxolitinib—CAMK1—hematopoietic system—hematologic cancer	0.000449	0.0107	CbGeAlD
Ruxolitinib—PLK1—gonad—hematologic cancer	0.000437	0.0104	CbGeAlD
Ruxolitinib—MARK2—hematopoietic system—hematologic cancer	0.000436	0.0104	CbGeAlD
Ruxolitinib—ANKK1—testis—hematologic cancer	0.000424	0.0101	CbGeAlD
Ruxolitinib—CYP3A4—Dexamethasone—hematologic cancer	0.000391	0.00284	CbGbCtD
Ruxolitinib—PRKG2—lung—hematologic cancer	0.000372	0.00888	CbGeAlD
Ruxolitinib—JAK3—hematopoietic system—hematologic cancer	0.00037	0.00883	CbGeAlD
Ruxolitinib—JAK1—hematopoietic system—hematologic cancer	0.000368	0.00878	CbGeAlD
Ruxolitinib—PLK4—hematopoietic system—hematologic cancer	0.000366	0.00872	CbGeAlD
Ruxolitinib—DCLK3—blood—hematologic cancer	0.000361	0.00861	CbGeAlD
Ruxolitinib—PRKG2—testis—hematologic cancer	0.000351	0.00837	CbGeAlD
Ruxolitinib—PRKCE—lung—hematologic cancer	0.000347	0.00829	CbGeAlD
Ruxolitinib—STK16—hematopoietic system—hematologic cancer	0.000345	0.00824	CbGeAlD
Ruxolitinib—HIPK2—hematopoietic system—hematologic cancer	0.000344	0.00819	CbGeAlD
Ruxolitinib—CAMK1—gonad—hematologic cancer	0.000341	0.00814	CbGeAlD
Ruxolitinib—PLK1—lung—hematologic cancer	0.000334	0.00796	CbGeAlD
Ruxolitinib—RPS6KA6—lung—hematologic cancer	0.000334	0.00796	CbGeAlD
Ruxolitinib—PRKCE—testis—hematologic cancer	0.000328	0.00782	CbGeAlD
Ruxolitinib—CYP3A4—Doxorubicin—hematologic cancer	0.000325	0.00235	CbGbCtD
Ruxolitinib—PLK3—blood—hematologic cancer	0.000318	0.00758	CbGeAlD
Ruxolitinib—ROCK1—hematopoietic system—hematologic cancer	0.000317	0.00756	CbGeAlD
Ruxolitinib—MAST1—testis—hematologic cancer	0.000315	0.00751	CbGeAlD
Ruxolitinib—RPS6KA6—testis—hematologic cancer	0.000315	0.00751	CbGeAlD
Ruxolitinib—PLK1—testis—hematologic cancer	0.000315	0.00751	CbGeAlD
Ruxolitinib—DYRK1A—hematopoietic system—hematologic cancer	0.000309	0.00737	CbGeAlD
Ruxolitinib—BMPR2—hematopoietic system—hematologic cancer	0.000308	0.00734	CbGeAlD
Ruxolitinib—DCLK3—testis—hematologic cancer	0.000299	0.00712	CbGeAlD
Ruxolitinib—CAMK1—blood—hematologic cancer	0.000297	0.00709	CbGeAlD
Ruxolitinib—MARK2—blood—hematologic cancer	0.000289	0.00688	CbGeAlD
Ruxolitinib—JAK1—gonad—hematologic cancer	0.00028	0.00667	CbGeAlD
Ruxolitinib—PLK3—lung—hematologic cancer	0.000279	0.00664	CbGeAlD
Ruxolitinib—PLK4—gonad—hematologic cancer	0.000278	0.00663	CbGeAlD
Ruxolitinib—LRRK2—hematopoietic system—hematologic cancer	0.000273	0.00651	CbGeAlD
Ruxolitinib—PHKG2—gonad—hematologic cancer	0.000271	0.00648	CbGeAlD
Ruxolitinib—LTK—lung—hematologic cancer	0.000269	0.00642	CbGeAlD
Ruxolitinib—TAOK2—blood—hematologic cancer	0.000267	0.00637	CbGeAlD
Ruxolitinib—PLK3—testis—hematologic cancer	0.000263	0.00627	CbGeAlD
Ruxolitinib—HIPK2—gonad—hematologic cancer	0.000261	0.00623	CbGeAlD
Ruxolitinib—CAMK1—lung—hematologic cancer	0.000261	0.00621	CbGeAlD
Ruxolitinib—LTK—testis—hematologic cancer	0.000254	0.00605	CbGeAlD
Ruxolitinib—MARK2—lung—hematologic cancer	0.000253	0.00603	CbGeAlD
Ruxolitinib—MAP3K2—hematopoietic system—hematologic cancer	0.00025	0.00597	CbGeAlD
Ruxolitinib—CLK2—gonad—hematologic cancer	0.000249	0.00593	CbGeAlD
Ruxolitinib—CAMK1—testis—hematologic cancer	0.000246	0.00586	CbGeAlD
Ruxolitinib—JAK3—blood—hematologic cancer	0.000245	0.00585	CbGeAlD
Ruxolitinib—JAK1—blood—hematologic cancer	0.000244	0.00581	CbGeAlD
Ruxolitinib—TYK2—hematopoietic system—hematologic cancer	0.000243	0.0058	CbGeAlD
Ruxolitinib—PLK4—blood—hematologic cancer	0.000242	0.00578	CbGeAlD
Ruxolitinib—ROCK1—gonad—hematologic cancer	0.000241	0.00575	CbGeAlD
Ruxolitinib—MKNK2—hematopoietic system—hematologic cancer	0.00024	0.00573	CbGeAlD
Ruxolitinib—IRAK1—hematopoietic system—hematologic cancer	0.00024	0.00573	CbGeAlD
Ruxolitinib—MARK2—testis—hematologic cancer	0.000239	0.00569	CbGeAlD
Ruxolitinib—CAMK1D—blood—hematologic cancer	0.000238	0.00568	CbGeAlD
Ruxolitinib—PRKCE—lymph node—hematologic cancer	0.000238	0.00567	CbGeAlD
Ruxolitinib—JAK1—bone marrow—hematologic cancer	0.000236	0.00563	CbGeAlD
Ruxolitinib—DYRK1A—gonad—hematologic cancer	0.000235	0.0056	CbGeAlD
Ruxolitinib—PLK4—bone marrow—hematologic cancer	0.000234	0.00559	CbGeAlD
Ruxolitinib—RET—hematopoietic system—hematologic cancer	0.000234	0.00559	CbGeAlD
Ruxolitinib—TAOK2—lung—hematologic cancer	0.000234	0.00558	CbGeAlD
Ruxolitinib—DAPK2—blood—hematologic cancer	0.000233	0.00555	CbGeAlD
Ruxolitinib—STK16—blood—hematologic cancer	0.000229	0.00546	CbGeAlD
Ruxolitinib—PLK1—lymph node—hematologic cancer	0.000228	0.00544	CbGeAlD
Ruxolitinib—RPS6KA6—lymph node—hematologic cancer	0.000228	0.00544	CbGeAlD
Ruxolitinib—DAPK2—bone marrow—hematologic cancer	0.000225	0.00537	CbGeAlD
Ruxolitinib—JAK2—hematopoietic system—hematologic cancer	0.000221	0.00528	CbGeAlD
Ruxolitinib—TAOK2—testis—hematologic cancer	0.000221	0.00527	CbGeAlD
Ruxolitinib—DAPK3—blood—hematologic cancer	0.000219	0.00522	CbGeAlD
Ruxolitinib—CLK2—blood—hematologic cancer	0.000217	0.00517	CbGeAlD
Ruxolitinib—JAK3—lung—hematologic cancer	0.000215	0.00513	CbGeAlD
Ruxolitinib—DCLK1—lung—hematologic cancer	0.000214	0.0051	CbGeAlD
Ruxolitinib—JAK1—lung—hematologic cancer	0.000214	0.0051	CbGeAlD
Ruxolitinib—MAP3K3—hematopoietic system—hematologic cancer	0.000213	0.00509	CbGeAlD
Ruxolitinib—PLK4—lung—hematologic cancer	0.000212	0.00507	CbGeAlD
Ruxolitinib—ROCK1—blood—hematologic cancer	0.00021	0.00501	CbGeAlD
Ruxolitinib—CLK2—bone marrow—hematologic cancer	0.00021	0.005	CbGeAlD
Ruxolitinib—BMP2K—gonad—hematologic cancer	0.000209	0.005	CbGeAlD
Ruxolitinib—CAMK1D—lung—hematologic cancer	0.000209	0.00498	CbGeAlD
Ruxolitinib—LRRK2—gonad—hematologic cancer	0.000208	0.00495	CbGeAlD
Ruxolitinib—PHKG2—lung—hematologic cancer	0.000207	0.00495	CbGeAlD
Ruxolitinib—DAPK2—lung—hematologic cancer	0.000204	0.00486	CbGeAlD
Ruxolitinib—JAK3—testis—hematologic cancer	0.000203	0.00484	CbGeAlD
Ruxolitinib—JAK1—testis—hematologic cancer	0.000202	0.00481	CbGeAlD
Ruxolitinib—DCLK1—testis—hematologic cancer	0.000202	0.00481	CbGeAlD
Ruxolitinib—STK16—lung—hematologic cancer	0.000201	0.00478	CbGeAlD
Ruxolitinib—PLK4—testis—hematologic cancer	0.0002	0.00478	CbGeAlD
Ruxolitinib—HIPK2—lung—hematologic cancer	0.0002	0.00476	CbGeAlD
Ruxolitinib—CAMK1D—testis—hematologic cancer	0.000197	0.00469	CbGeAlD
Ruxolitinib—PHKG2—testis—hematologic cancer	0.000196	0.00467	CbGeAlD
Ruxolitinib—MAP3K19—lung—hematologic cancer	0.000195	0.00466	CbGeAlD
Ruxolitinib—NUAK2—blood—hematologic cancer	0.000195	0.00465	CbGeAlD
Ruxolitinib—TAOK3—hematopoietic system—hematologic cancer	0.000195	0.00464	CbGeAlD
Ruxolitinib—DAPK2—testis—hematologic cancer	0.000192	0.00459	CbGeAlD
Ruxolitinib—DAPK3—lung—hematologic cancer	0.000192	0.00457	CbGeAlD
Ruxolitinib—PLK3—lymph node—hematologic cancer	0.000191	0.00454	CbGeAlD
Ruxolitinib—MAP3K2—gonad—hematologic cancer	0.00019	0.00454	CbGeAlD
Ruxolitinib—CLK2—lung—hematologic cancer	0.00019	0.00453	CbGeAlD
Ruxolitinib—STK16—testis—hematologic cancer	0.000189	0.00451	CbGeAlD
Ruxolitinib—NUAK2—bone marrow—hematologic cancer	0.000189	0.0045	CbGeAlD
Ruxolitinib—HIPK2—testis—hematologic cancer	0.000188	0.00449	CbGeAlD
Ruxolitinib—MAP3K19—testis—hematologic cancer	0.000184	0.0044	CbGeAlD
Ruxolitinib—ROCK1—lung—hematologic cancer	0.000184	0.00439	CbGeAlD
Ruxolitinib—LTK—lymph node—hematologic cancer	0.000184	0.00439	CbGeAlD
Ruxolitinib—MKNK2—gonad—hematologic cancer	0.000183	0.00436	CbGeAlD
Ruxolitinib—BMP2K—blood—hematologic cancer	0.000183	0.00435	CbGeAlD
Ruxolitinib—CAMK2G—blood—hematologic cancer	0.000183	0.00435	CbGeAlD
Ruxolitinib—DAPK3—testis—hematologic cancer	0.000181	0.00431	CbGeAlD
Ruxolitinib—LRRK2—blood—hematologic cancer	0.000181	0.00431	CbGeAlD
Ruxolitinib—DYRK1A—lung—hematologic cancer	0.00018	0.00428	CbGeAlD
Ruxolitinib—CLK2—testis—hematologic cancer	0.000179	0.00427	CbGeAlD
Ruxolitinib—BMPR2—lung—hematologic cancer	0.000179	0.00426	CbGeAlD
Ruxolitinib—CAMK1—lymph node—hematologic cancer	0.000178	0.00425	CbGeAlD
Ruxolitinib—CAMK2G—bone marrow—hematologic cancer	0.000177	0.00421	CbGeAlD
Ruxolitinib—BMP2K—bone marrow—hematologic cancer	0.000177	0.00421	CbGeAlD
Ruxolitinib—LRRK2—bone marrow—hematologic cancer	0.000175	0.00417	CbGeAlD
Ruxolitinib—ROCK1—testis—hematologic cancer	0.000174	0.00414	CbGeAlD
Ruxolitinib—MARK2—lymph node—hematologic cancer	0.000173	0.00413	CbGeAlD
Ruxolitinib—NUAK2—lung—hematologic cancer	0.000171	0.00408	CbGeAlD
Ruxolitinib—DYRK1A—testis—hematologic cancer	0.000169	0.00404	CbGeAlD
Ruxolitinib—BMPR2—testis—hematologic cancer	0.000169	0.00402	CbGeAlD
Ruxolitinib—JAK2—gonad—hematologic cancer	0.000168	0.00401	CbGeAlD
Ruxolitinib—MAP3K2—blood—hematologic cancer	0.000166	0.00395	CbGeAlD
Ruxolitinib—MAP3K7—blood—hematologic cancer	0.000164	0.00392	CbGeAlD
Ruxolitinib—MAP3K3—gonad—hematologic cancer	0.000162	0.00387	CbGeAlD
Ruxolitinib—NUAK2—testis—hematologic cancer	0.000161	0.00385	CbGeAlD
Ruxolitinib—TYK2—blood—hematologic cancer	0.000161	0.00384	CbGeAlD
Ruxolitinib—MAP3K2—bone marrow—hematologic cancer	0.00016	0.00382	CbGeAlD
Ruxolitinib—TAOK2—lymph node—hematologic cancer	0.00016	0.00382	CbGeAlD
Ruxolitinib—BMP2K—lung—hematologic cancer	0.00016	0.00382	CbGeAlD
Ruxolitinib—CAMK2G—lung—hematologic cancer	0.00016	0.00382	CbGeAlD
Ruxolitinib—MKNK2—blood—hematologic cancer	0.000159	0.00379	CbGeAlD
Ruxolitinib—IRAK1—blood—hematologic cancer	0.000159	0.00379	CbGeAlD
Ruxolitinib—MAP3K7—bone marrow—hematologic cancer	0.000159	0.00379	CbGeAlD
Ruxolitinib—LRRK2—lung—hematologic cancer	0.000159	0.00378	CbGeAlD
Ruxolitinib—TYK2—bone marrow—hematologic cancer	0.000156	0.00372	CbGeAlD
Ruxolitinib—RET—blood—hematologic cancer	0.000155	0.0037	CbGeAlD
Ruxolitinib—IRAK1—bone marrow—hematologic cancer	0.000154	0.00367	CbGeAlD
Ruxolitinib—MKNK2—bone marrow—hematologic cancer	0.000154	0.00367	CbGeAlD
Ruxolitinib—BMP2K—testis—hematologic cancer	0.000151	0.0036	CbGeAlD
Ruxolitinib—CAMK2G—testis—hematologic cancer	0.000151	0.0036	CbGeAlD
Ruxolitinib—LRRK2—testis—hematologic cancer	0.00015	0.00357	CbGeAlD
Ruxolitinib—JAK3—lymph node—hematologic cancer	0.000147	0.00351	CbGeAlD
Ruxolitinib—JAK2—blood—hematologic cancer	0.000147	0.0035	CbGeAlD
Ruxolitinib—DCLK1—lymph node—hematologic cancer	0.000146	0.00349	CbGeAlD
Ruxolitinib—JAK1—lymph node—hematologic cancer	0.000146	0.00349	CbGeAlD
Ruxolitinib—MAP3K2—lung—hematologic cancer	0.000145	0.00346	CbGeAlD
Ruxolitinib—PLK4—lymph node—hematologic cancer	0.000145	0.00346	CbGeAlD
Ruxolitinib—MAP3K7—lung—hematologic cancer	0.000144	0.00343	CbGeAlD
Ruxolitinib—CAMK1D—lymph node—hematologic cancer	0.000143	0.0034	CbGeAlD
Ruxolitinib—JAK2—bone marrow—hematologic cancer	0.000142	0.00338	CbGeAlD
Ruxolitinib—PHKG2—lymph node—hematologic cancer	0.000142	0.00338	CbGeAlD
Ruxolitinib—MAP3K3—blood—hematologic cancer	0.000141	0.00337	CbGeAlD
Ruxolitinib—TYK2—lung—hematologic cancer	0.000141	0.00337	CbGeAlD
Ruxolitinib—MKNK2—lung—hematologic cancer	0.000139	0.00333	CbGeAlD
Ruxolitinib—IRAK1—lung—hematologic cancer	0.000139	0.00333	CbGeAlD
Ruxolitinib—DAPK2—lymph node—hematologic cancer	0.000139	0.00333	CbGeAlD
Ruxolitinib—STK16—lymph node—hematologic cancer	0.000137	0.00327	CbGeAlD
Ruxolitinib—MAP3K2—testis—hematologic cancer	0.000137	0.00327	CbGeAlD
Ruxolitinib—MAP3K3—bone marrow—hematologic cancer	0.000137	0.00326	CbGeAlD
Ruxolitinib—HIPK2—lymph node—hematologic cancer	0.000136	0.00325	CbGeAlD
Ruxolitinib—MAP3K7—testis—hematologic cancer	0.000136	0.00324	CbGeAlD
Ruxolitinib—TYK2—testis—hematologic cancer	0.000133	0.00318	CbGeAlD
Ruxolitinib—IRAK1—testis—hematologic cancer	0.000132	0.00314	CbGeAlD
Ruxolitinib—MKNK2—testis—hematologic cancer	0.000132	0.00314	CbGeAlD
Ruxolitinib—DAPK3—lymph node—hematologic cancer	0.000131	0.00313	CbGeAlD
Ruxolitinib—CLK2—lymph node—hematologic cancer	0.00013	0.0031	CbGeAlD
Ruxolitinib—TAOK3—blood—hematologic cancer	0.000129	0.00307	CbGeAlD
Ruxolitinib—JAK2—lung—hematologic cancer	0.000129	0.00307	CbGeAlD
Ruxolitinib—RET—testis—hematologic cancer	0.000128	0.00306	CbGeAlD
Ruxolitinib—TAOK3—bone marrow—hematologic cancer	0.000125	0.00297	CbGeAlD
Ruxolitinib—MAP3K3—lung—hematologic cancer	0.000124	0.00296	CbGeAlD
Ruxolitinib—DYRK1A—lymph node—hematologic cancer	0.000123	0.00293	CbGeAlD
Ruxolitinib—BMPR2—lymph node—hematologic cancer	0.000122	0.00292	CbGeAlD
Ruxolitinib—JAK2—testis—hematologic cancer	0.000121	0.00289	CbGeAlD
Ruxolitinib—MAP3K3—testis—hematologic cancer	0.000117	0.00279	CbGeAlD
Ruxolitinib—NUAK2—lymph node—hematologic cancer	0.000117	0.00279	CbGeAlD
Ruxolitinib—TAOK3—lung—hematologic cancer	0.000113	0.00269	CbGeAlD
Ruxolitinib—BMP2K—lymph node—hematologic cancer	0.000109	0.00261	CbGeAlD
Ruxolitinib—CAMK2G—lymph node—hematologic cancer	0.000109	0.00261	CbGeAlD
Ruxolitinib—LRRK2—lymph node—hematologic cancer	0.000108	0.00259	CbGeAlD
Ruxolitinib—TAOK3—testis—hematologic cancer	0.000107	0.00254	CbGeAlD
Ruxolitinib—MAP3K2—lymph node—hematologic cancer	9.94e-05	0.00237	CbGeAlD
Ruxolitinib—MAP3K7—lymph node—hematologic cancer	9.84e-05	0.00235	CbGeAlD
Ruxolitinib—TYK2—lymph node—hematologic cancer	9.67e-05	0.00231	CbGeAlD
Ruxolitinib—MKNK2—lymph node—hematologic cancer	9.54e-05	0.00228	CbGeAlD
Ruxolitinib—IRAK1—lymph node—hematologic cancer	9.54e-05	0.00228	CbGeAlD
Ruxolitinib—RET—lymph node—hematologic cancer	9.3e-05	0.00222	CbGeAlD
Ruxolitinib—JAK2—lymph node—hematologic cancer	8.79e-05	0.0021	CbGeAlD
Ruxolitinib—MAP3K3—lymph node—hematologic cancer	8.48e-05	0.00202	CbGeAlD
Ruxolitinib—TAOK3—lymph node—hematologic cancer	7.73e-05	0.00184	CbGeAlD
Ruxolitinib—PLK1—Nilotinib—Imatinib—hematologic cancer	6.23e-05	0.0356	CbGdCrCtD
Ruxolitinib—PLK1—Chlorambucil—Melphalan—hematologic cancer	5.99e-05	0.0342	CbGdCrCtD
Ruxolitinib—CYP3A4—hematopoietic system—hematologic cancer	5.91e-05	0.00141	CbGeAlD
Ruxolitinib—DYRK1A—Topotecan—Irinotecan—hematologic cancer	5.06e-05	0.0289	CbGdCrCtD
Ruxolitinib—PLK1—Trifluridine—Pentostatin—hematologic cancer	4.63e-05	0.0265	CbGdCrCtD
Ruxolitinib—CYP3A4—blood—hematologic cancer	3.92e-05	0.000934	CbGeAlD
Ruxolitinib—PLK1—Vidarabine—Pentostatin—hematologic cancer	3.84e-05	0.022	CbGdCrCtD
Ruxolitinib—PLK1—Adenosine—Pentostatin—hematologic cancer	3.84e-05	0.022	CbGdCrCtD
Ruxolitinib—CAMK2G—Azacitidine—Pentostatin—hematologic cancer	3.58e-05	0.0205	CbGdCrCtD
Ruxolitinib—PLK1—Topotecan—Irinotecan—hematologic cancer	3.46e-05	0.0198	CbGdCrCtD
Ruxolitinib—PLK4—Topotecan—Irinotecan—hematologic cancer	3.46e-05	0.0198	CbGdCrCtD
Ruxolitinib—PLK4—Etoposide—Teniposide—hematologic cancer	3.43e-05	0.0196	CbGdCrCtD
Ruxolitinib—PLK1—Etoposide—Teniposide—hematologic cancer	3.43e-05	0.0196	CbGdCrCtD
Ruxolitinib—PLK1—Adenosine—Clofarabine—hematologic cancer	3.42e-05	0.0196	CbGdCrCtD
Ruxolitinib—PLK1—Vidarabine—Clofarabine—hematologic cancer	3.42e-05	0.0196	CbGdCrCtD
Ruxolitinib—DYRK1A—Idarubicin—Daunorubicin—hematologic cancer	3.42e-05	0.0195	CbGdCrCtD
Ruxolitinib—DYRK1A—Epirubicin—Daunorubicin—hematologic cancer	3.42e-05	0.0195	CbGdCrCtD
Ruxolitinib—DYRK1A—Doxorubicin—Daunorubicin—hematologic cancer	3.42e-05	0.0195	CbGdCrCtD
Ruxolitinib—PLK1—Vidarabine—Nelarabine—hematologic cancer	3.22e-05	0.0184	CbGdCrCtD
Ruxolitinib—PLK1—Adenosine—Nelarabine—hematologic cancer	3.22e-05	0.0184	CbGdCrCtD
Ruxolitinib—CAMK2G—Azacitidine—Clofarabine—hematologic cancer	3.19e-05	0.0183	CbGdCrCtD
Ruxolitinib—CAMK2G—Azacitidine—Nelarabine—hematologic cancer	3e-05	0.0172	CbGdCrCtD
Ruxolitinib—Anaemia—Cisplatin—hematologic cancer	2.9e-05	0.000446	CcSEcCtD
Ruxolitinib—Dizziness—Imatinib—hematologic cancer	2.89e-05	0.000444	CcSEcCtD
Ruxolitinib—Skin disorder—Ifosfamide—hematologic cancer	2.89e-05	0.000444	CcSEcCtD
Ruxolitinib—Infection—Vincristine—hematologic cancer	2.88e-05	0.000443	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—hematologic cancer	2.85e-05	0.000438	CcSEcCtD
Ruxolitinib—Nervous system disorder—Vincristine—hematologic cancer	2.84e-05	0.000437	CcSEcCtD
Ruxolitinib—Dizziness—Cladribine—hematologic cancer	2.84e-05	0.000437	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Vincristine—hematologic cancer	2.84e-05	0.000436	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Thiotepa—hematologic cancer	2.82e-05	0.000434	CcSEcCtD
Ruxolitinib—Fatigue—Thiotepa—hematologic cancer	2.82e-05	0.000433	CcSEcCtD
Ruxolitinib—Asthenia—Melphalan—hematologic cancer	2.81e-05	0.000432	CcSEcCtD
Ruxolitinib—Infection—Irinotecan—hematologic cancer	2.81e-05	0.000431	CcSEcCtD
Ruxolitinib—Infection—Mitoxantrone—hematologic cancer	2.81e-05	0.000431	CcSEcCtD
Ruxolitinib—PLK1—Trifluridine—Cladribine—hematologic cancer	2.79e-05	0.016	CbGdCrCtD
Ruxolitinib—Pruritus—Melphalan—hematologic cancer	2.77e-05	0.000426	CcSEcCtD
Ruxolitinib—Body temperature increased—Bortezomib—hematologic cancer	2.77e-05	0.000426	CcSEcCtD
Ruxolitinib—Nervous system disorder—Irinotecan—hematologic cancer	2.77e-05	0.000426	CcSEcCtD
Ruxolitinib—Neutropenia—Prednisone—hematologic cancer	2.77e-05	0.000425	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Irinotecan—hematologic cancer	2.77e-05	0.000425	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Mitoxantrone—hematologic cancer	2.77e-05	0.000425	CcSEcCtD
Ruxolitinib—Headache—Nilotinib—hematologic cancer	2.76e-05	0.000423	CcSEcCtD
Ruxolitinib—Body temperature increased—Bleomycin—hematologic cancer	2.75e-05	0.000423	CcSEcCtD
Ruxolitinib—Skin disorder—Mitoxantrone—hematologic cancer	2.74e-05	0.000422	CcSEcCtD
Ruxolitinib—Headache—Imatinib—hematologic cancer	2.74e-05	0.000421	CcSEcCtD
Ruxolitinib—Haemoglobin—Dexamethasone—hematologic cancer	2.74e-05	0.00042	CcSEcCtD
Ruxolitinib—Haemoglobin—Betamethasone—hematologic cancer	2.74e-05	0.00042	CcSEcCtD
Ruxolitinib—Asthenia—Lenalidomide—hematologic cancer	2.73e-05	0.00042	CcSEcCtD
Ruxolitinib—Infection—Gemcitabine—hematologic cancer	2.73e-05	0.00042	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Thalidomide—hematologic cancer	2.73e-05	0.00042	CcSEcCtD
Ruxolitinib—Fatigue—Thalidomide—hematologic cancer	2.73e-05	0.000419	CcSEcCtD
Ruxolitinib—Dizziness—Vinblastine—hematologic cancer	2.73e-05	0.000419	CcSEcCtD
Ruxolitinib—Haemorrhage—Betamethasone—hematologic cancer	2.72e-05	0.000418	CcSEcCtD
Ruxolitinib—Haemorrhage—Dexamethasone—hematologic cancer	2.72e-05	0.000418	CcSEcCtD
Ruxolitinib—Body temperature increased—Vinorelbine—hematologic cancer	2.71e-05	0.000416	CcSEcCtD
Ruxolitinib—Nervous system disorder—Gemcitabine—hematologic cancer	2.7e-05	0.000415	CcSEcCtD
Ruxolitinib—Pruritus—Lenalidomide—hematologic cancer	2.7e-05	0.000414	CcSEcCtD
Ruxolitinib—Asthenia—Hydroxyurea—hematologic cancer	2.7e-05	0.000414	CcSEcCtD
Ruxolitinib—Weight increased—Prednisone—hematologic cancer	2.69e-05	0.000414	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Gemcitabine—hematologic cancer	2.69e-05	0.000414	CcSEcCtD
Ruxolitinib—Headache—Cladribine—hematologic cancer	2.69e-05	0.000414	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Epirubicin—hematologic cancer	2.68e-05	0.000412	CcSEcCtD
Ruxolitinib—Weight decreased—Prednisone—hematologic cancer	2.68e-05	0.000412	CcSEcCtD
Ruxolitinib—Skin disorder—Gemcitabine—hematologic cancer	2.67e-05	0.000411	CcSEcCtD
Ruxolitinib—Anaemia—Etoposide—hematologic cancer	2.66e-05	0.000409	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—hematologic cancer	2.66e-05	0.000408	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Carmustine—hematologic cancer	2.62e-05	0.000403	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Alitretinoin—hematologic cancer	2.6e-05	0.000399	CcSEcCtD
Ruxolitinib—Fatigue—Alitretinoin—hematologic cancer	2.6e-05	0.000399	CcSEcCtD
Ruxolitinib—DYRK1A—Daunorubicin—Idarubicin—hematologic cancer	2.59e-05	0.0148	CbGdCrCtD
Ruxolitinib—DYRK1A—Doxorubicin—Idarubicin—hematologic cancer	2.59e-05	0.0148	CbGdCrCtD
Ruxolitinib—DYRK1A—Epirubicin—Idarubicin—hematologic cancer	2.59e-05	0.0148	CbGdCrCtD
Ruxolitinib—Body temperature increased—Thiotepa—hematologic cancer	2.59e-05	0.000397	CcSEcCtD
Ruxolitinib—Headache—Vinblastine—hematologic cancer	2.58e-05	0.000397	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Ifosfamide—hematologic cancer	2.57e-05	0.000395	CcSEcCtD
Ruxolitinib—Fatigue—Ifosfamide—hematologic cancer	2.56e-05	0.000394	CcSEcCtD
Ruxolitinib—Infection—Cisplatin—hematologic cancer	2.55e-05	0.000391	CcSEcCtD
Ruxolitinib—Dizziness—Lenalidomide—hematologic cancer	2.52e-05	0.000387	CcSEcCtD
Ruxolitinib—Asthenia—Bortezomib—hematologic cancer	2.52e-05	0.000387	CcSEcCtD
Ruxolitinib—Nervous system disorder—Cisplatin—hematologic cancer	2.52e-05	0.000386	CcSEcCtD
Ruxolitinib—PLK1—Adenosine—Fludarabine—hematologic cancer	2.51e-05	0.0144	CbGdCrCtD
Ruxolitinib—PLK1—Vidarabine—Fludarabine—hematologic cancer	2.51e-05	0.0144	CbGdCrCtD
Ruxolitinib—Thrombocytopenia—Cisplatin—hematologic cancer	2.51e-05	0.000386	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Vincristine—hematologic cancer	2.5e-05	0.000385	CcSEcCtD
Ruxolitinib—Body temperature increased—Thalidomide—hematologic cancer	2.5e-05	0.000384	CcSEcCtD
Ruxolitinib—Fatigue—Vincristine—hematologic cancer	2.5e-05	0.000384	CcSEcCtD
Ruxolitinib—Asthenia—Bleomycin—hematologic cancer	2.5e-05	0.000384	CcSEcCtD
Ruxolitinib—Skin disorder—Cisplatin—hematologic cancer	2.49e-05	0.000383	CcSEcCtD
Ruxolitinib—Dizziness—Hydroxyurea—hematologic cancer	2.49e-05	0.000382	CcSEcCtD
Ruxolitinib—Pruritus—Bortezomib—hematologic cancer	2.48e-05	0.000381	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Doxorubicin—hematologic cancer	2.48e-05	0.000381	CcSEcCtD
Ruxolitinib—Pruritus—Bleomycin—hematologic cancer	2.46e-05	0.000378	CcSEcCtD
Ruxolitinib—Asthenia—Vinorelbine—hematologic cancer	2.46e-05	0.000378	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Irinotecan—hematologic cancer	2.44e-05	0.000375	CcSEcCtD
Ruxolitinib—Fatigue—Mitoxantrone—hematologic cancer	2.44e-05	0.000374	CcSEcCtD
Ruxolitinib—Fatigue—Irinotecan—hematologic cancer	2.44e-05	0.000374	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—hematologic cancer	2.43e-05	0.000374	CcSEcCtD
Ruxolitinib—Pruritus—Vinorelbine—hematologic cancer	2.42e-05	0.000372	CcSEcCtD
Ruxolitinib—Body temperature increased—Carmustine—hematologic cancer	2.4e-05	0.000369	CcSEcCtD
Ruxolitinib—Headache—Lenalidomide—hematologic cancer	2.39e-05	0.000367	CcSEcCtD
Ruxolitinib—Haemoglobin—Prednisone—hematologic cancer	2.38e-05	0.000366	CcSEcCtD
Ruxolitinib—PLK1—Floxuridine—Pentostatin—hematologic cancer	2.38e-05	0.0136	CbGdCrCtD
Ruxolitinib—Body temperature increased—Alitretinoin—hematologic cancer	2.38e-05	0.000366	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Gemcitabine—hematologic cancer	2.38e-05	0.000365	CcSEcCtD
Ruxolitinib—PLK1—Vidarabine—Cytarabine—hematologic cancer	2.37e-05	0.0136	CbGdCrCtD
Ruxolitinib—PLK1—Adenosine—Cytarabine—hematologic cancer	2.37e-05	0.0136	CbGdCrCtD
Ruxolitinib—Fatigue—Gemcitabine—hematologic cancer	2.37e-05	0.000364	CcSEcCtD
Ruxolitinib—Haemorrhage—Prednisone—hematologic cancer	2.37e-05	0.000364	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Epirubicin—hematologic cancer	2.36e-05	0.000363	CcSEcCtD
Ruxolitinib—Headache—Hydroxyurea—hematologic cancer	2.35e-05	0.000362	CcSEcCtD
Ruxolitinib—Body temperature increased—Ifosfamide—hematologic cancer	2.35e-05	0.000361	CcSEcCtD
Ruxolitinib—Pancytopenia—Methotrexate—hematologic cancer	2.35e-05	0.000361	CcSEcCtD
Ruxolitinib—Asthenia—Thiotepa—hematologic cancer	2.35e-05	0.000361	CcSEcCtD
Ruxolitinib—CAMK2G—Azacitidine—Fludarabine—hematologic cancer	2.34e-05	0.0134	CbGdCrCtD
Ruxolitinib—PLK1—Epirubicin—Daunorubicin—hematologic cancer	2.33e-05	0.0133	CbGdCrCtD
Ruxolitinib—PLK4—Doxorubicin—Daunorubicin—hematologic cancer	2.33e-05	0.0133	CbGdCrCtD
Ruxolitinib—PLK1—Doxorubicin—Daunorubicin—hematologic cancer	2.33e-05	0.0133	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Daunorubicin—hematologic cancer	2.33e-05	0.0133	CbGdCrCtD
Ruxolitinib—PLK4—Epirubicin—Daunorubicin—hematologic cancer	2.33e-05	0.0133	CbGdCrCtD
Ruxolitinib—PLK1—Idarubicin—Daunorubicin—hematologic cancer	2.33e-05	0.0133	CbGdCrCtD
Ruxolitinib—Infection—Etoposide—hematologic cancer	2.33e-05	0.000359	CcSEcCtD
Ruxolitinib—Dizziness—Bortezomib—hematologic cancer	2.32e-05	0.000356	CcSEcCtD
Ruxolitinib—Neutropenia—Methotrexate—hematologic cancer	2.31e-05	0.000356	CcSEcCtD
Ruxolitinib—Pruritus—Thiotepa—hematologic cancer	2.31e-05	0.000356	CcSEcCtD
Ruxolitinib—PLK1—Adenosine—Cladribine—hematologic cancer	2.31e-05	0.0132	CbGdCrCtD
Ruxolitinib—PLK1—Vidarabine—Cladribine—hematologic cancer	2.31e-05	0.0132	CbGdCrCtD
Ruxolitinib—Thrombocytopenia—Etoposide—hematologic cancer	2.3e-05	0.000353	CcSEcCtD
Ruxolitinib—Body temperature increased—Vincristine—hematologic cancer	2.29e-05	0.000352	CcSEcCtD
Ruxolitinib—Skin disorder—Etoposide—hematologic cancer	2.28e-05	0.000351	CcSEcCtD
Ruxolitinib—Asthenia—Thalidomide—hematologic cancer	2.27e-05	0.000349	CcSEcCtD
Ruxolitinib—Dizziness—Vinorelbine—hematologic cancer	2.26e-05	0.000348	CcSEcCtD
Ruxolitinib—Pruritus—Thalidomide—hematologic cancer	2.24e-05	0.000344	CcSEcCtD
Ruxolitinib—Body temperature increased—Mitoxantrone—hematologic cancer	2.23e-05	0.000343	CcSEcCtD
Ruxolitinib—Body temperature increased—Irinotecan—hematologic cancer	2.23e-05	0.000343	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Cisplatin—hematologic cancer	2.21e-05	0.00034	CcSEcCtD
Ruxolitinib—CAMK2G—Azacitidine—Gemcitabine—hematologic cancer	2.21e-05	0.0127	CbGdCrCtD
Ruxolitinib—CAMK2G—Azacitidine—Cytarabine—hematologic cancer	2.21e-05	0.0127	CbGdCrCtD
Ruxolitinib—Infestation NOS—Methotrexate—hematologic cancer	2.21e-05	0.000339	CcSEcCtD
Ruxolitinib—Infestation—Methotrexate—hematologic cancer	2.21e-05	0.000339	CcSEcCtD
Ruxolitinib—Pancytopenia—Epirubicin—hematologic cancer	2.2e-05	0.000338	CcSEcCtD
Ruxolitinib—Headache—Bortezomib—hematologic cancer	2.2e-05	0.000338	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Doxorubicin—hematologic cancer	2.19e-05	0.000336	CcSEcCtD
Ruxolitinib—Asthenia—Carmustine—hematologic cancer	2.18e-05	0.000335	CcSEcCtD
Ruxolitinib—Body temperature increased—Gemcitabine—hematologic cancer	2.18e-05	0.000334	CcSEcCtD
Ruxolitinib—Neutropenia—Epirubicin—hematologic cancer	2.17e-05	0.000333	CcSEcCtD
Ruxolitinib—Dizziness—Thiotepa—hematologic cancer	2.16e-05	0.000332	CcSEcCtD
Ruxolitinib—Asthenia—Alitretinoin—hematologic cancer	2.16e-05	0.000332	CcSEcCtD
Ruxolitinib—CAMK2G—Azacitidine—Cladribine—hematologic cancer	2.16e-05	0.0123	CbGdCrCtD
Ruxolitinib—Headache—Vinorelbine—hematologic cancer	2.15e-05	0.00033	CcSEcCtD
Ruxolitinib—Asthenia—Ifosfamide—hematologic cancer	2.13e-05	0.000328	CcSEcCtD
Ruxolitinib—Pruritus—Alitretinoin—hematologic cancer	2.13e-05	0.000327	CcSEcCtD
Ruxolitinib—Infection—Triamcinolone—hematologic cancer	2.12e-05	0.000325	CcSEcCtD
Ruxolitinib—Weight increased—Epirubicin—hematologic cancer	2.11e-05	0.000324	CcSEcCtD
Ruxolitinib—Pruritus—Ifosfamide—hematologic cancer	2.1e-05	0.000323	CcSEcCtD
Ruxolitinib—Haematuria—Methotrexate—hematologic cancer	2.1e-05	0.000323	CcSEcCtD
Ruxolitinib—Weight decreased—Epirubicin—hematologic cancer	2.1e-05	0.000322	CcSEcCtD
Ruxolitinib—Dizziness—Thalidomide—hematologic cancer	2.09e-05	0.000321	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Methotrexate—hematologic cancer	2.09e-05	0.000321	CcSEcCtD
Ruxolitinib—Epistaxis—Methotrexate—hematologic cancer	2.08e-05	0.00032	CcSEcCtD
Ruxolitinib—Asthenia—Vincristine—hematologic cancer	2.08e-05	0.00032	CcSEcCtD
Ruxolitinib—Infestation—Epirubicin—hematologic cancer	2.06e-05	0.000317	CcSEcCtD
Ruxolitinib—Infestation NOS—Epirubicin—hematologic cancer	2.06e-05	0.000317	CcSEcCtD
Ruxolitinib—Malnutrition—Prednisone—hematologic cancer	2.06e-05	0.000317	CcSEcCtD
Ruxolitinib—Headache—Thiotepa—hematologic cancer	2.05e-05	0.000315	CcSEcCtD
Ruxolitinib—Pancytopenia—Doxorubicin—hematologic cancer	2.04e-05	0.000313	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Etoposide—hematologic cancer	2.03e-05	0.000312	CcSEcCtD
Ruxolitinib—Body temperature increased—Cisplatin—hematologic cancer	2.03e-05	0.000311	CcSEcCtD
Ruxolitinib—Asthenia—Mitoxantrone—hematologic cancer	2.03e-05	0.000311	CcSEcCtD
Ruxolitinib—Asthenia—Irinotecan—hematologic cancer	2.03e-05	0.000311	CcSEcCtD
Ruxolitinib—Fatigue—Etoposide—hematologic cancer	2.03e-05	0.000311	CcSEcCtD
Ruxolitinib—Dizziness—Carmustine—hematologic cancer	2.01e-05	0.000309	CcSEcCtD
Ruxolitinib—Urinary tract infection—Epirubicin—hematologic cancer	2.01e-05	0.000308	CcSEcCtD
Ruxolitinib—Neutropenia—Doxorubicin—hematologic cancer	2e-05	0.000308	CcSEcCtD
Ruxolitinib—Haemoglobin—Methotrexate—hematologic cancer	1.99e-05	0.000306	CcSEcCtD
Ruxolitinib—Dizziness—Alitretinoin—hematologic cancer	1.99e-05	0.000306	CcSEcCtD
Ruxolitinib—PLK4—Menadione—Thalidomide—hematologic cancer	1.98e-05	0.0114	CbGdCrCtD
Ruxolitinib—PLK1—Menadione—Thalidomide—hematologic cancer	1.98e-05	0.0114	CbGdCrCtD
Ruxolitinib—Headache—Thalidomide—hematologic cancer	1.98e-05	0.000304	CcSEcCtD
Ruxolitinib—Haemorrhage—Methotrexate—hematologic cancer	1.98e-05	0.000304	CcSEcCtD
Ruxolitinib—Asthenia—Gemcitabine—hematologic cancer	1.97e-05	0.000303	CcSEcCtD
Ruxolitinib—Haematuria—Epirubicin—hematologic cancer	1.97e-05	0.000302	CcSEcCtD
Ruxolitinib—Dizziness—Ifosfamide—hematologic cancer	1.97e-05	0.000302	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Epirubicin—hematologic cancer	1.95e-05	0.0003	CcSEcCtD
Ruxolitinib—Weight increased—Doxorubicin—hematologic cancer	1.95e-05	0.0003	CcSEcCtD
Ruxolitinib—Epistaxis—Epirubicin—hematologic cancer	1.95e-05	0.000299	CcSEcCtD
Ruxolitinib—Pruritus—Gemcitabine—hematologic cancer	1.95e-05	0.000299	CcSEcCtD
Ruxolitinib—Weight decreased—Doxorubicin—hematologic cancer	1.94e-05	0.000298	CcSEcCtD
Ruxolitinib—Infection—Betamethasone—hematologic cancer	1.92e-05	0.000295	CcSEcCtD
Ruxolitinib—Infection—Dexamethasone—hematologic cancer	1.92e-05	0.000295	CcSEcCtD
Ruxolitinib—Dizziness—Vincristine—hematologic cancer	1.92e-05	0.000295	CcSEcCtD
Ruxolitinib—Infestation—Doxorubicin—hematologic cancer	1.91e-05	0.000294	CcSEcCtD
Ruxolitinib—Infestation NOS—Doxorubicin—hematologic cancer	1.91e-05	0.000294	CcSEcCtD
Ruxolitinib—Anaemia—Prednisone—hematologic cancer	1.91e-05	0.000293	CcSEcCtD
Ruxolitinib—Headache—Carmustine—hematologic cancer	1.9e-05	0.000292	CcSEcCtD
Ruxolitinib—Nervous system disorder—Dexamethasone—hematologic cancer	1.9e-05	0.000291	CcSEcCtD
Ruxolitinib—Nervous system disorder—Betamethasone—hematologic cancer	1.9e-05	0.000291	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Betamethasone—hematologic cancer	1.89e-05	0.000291	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Dexamethasone—hematologic cancer	1.89e-05	0.000291	CcSEcCtD
Ruxolitinib—Headache—Alitretinoin—hematologic cancer	1.89e-05	0.00029	CcSEcCtD
Ruxolitinib—Dizziness—Irinotecan—hematologic cancer	1.87e-05	0.000287	CcSEcCtD
Ruxolitinib—Haemoglobin—Epirubicin—hematologic cancer	1.86e-05	0.000286	CcSEcCtD
Ruxolitinib—Body temperature increased—Etoposide—hematologic cancer	1.86e-05	0.000285	CcSEcCtD
Ruxolitinib—Urinary tract infection—Doxorubicin—hematologic cancer	1.86e-05	0.000285	CcSEcCtD
Ruxolitinib—Haemorrhage—Epirubicin—hematologic cancer	1.85e-05	0.000285	CcSEcCtD
Ruxolitinib—Asthenia—Cisplatin—hematologic cancer	1.84e-05	0.000283	CcSEcCtD
Ruxolitinib—Fatigue—Triamcinolone—hematologic cancer	1.84e-05	0.000282	CcSEcCtD
Ruxolitinib—Haematuria—Doxorubicin—hematologic cancer	1.82e-05	0.00028	CcSEcCtD
Ruxolitinib—Headache—Vincristine—hematologic cancer	1.82e-05	0.000279	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Doxorubicin—hematologic cancer	1.81e-05	0.000278	CcSEcCtD
Ruxolitinib—PLK1—Cladribine—Pentostatin—hematologic cancer	1.8e-05	0.0103	CbGdCrCtD
Ruxolitinib—Epistaxis—Doxorubicin—hematologic cancer	1.8e-05	0.000277	CcSEcCtD
Ruxolitinib—Headache—Mitoxantrone—hematologic cancer	1.77e-05	0.000272	CcSEcCtD
Ruxolitinib—Headache—Irinotecan—hematologic cancer	1.77e-05	0.000272	CcSEcCtD
Ruxolitinib—PLK1—Doxorubicin—Idarubicin—hematologic cancer	1.77e-05	0.0101	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Idarubicin—hematologic cancer	1.77e-05	0.0101	CbGdCrCtD
Ruxolitinib—PLK4—Doxorubicin—Idarubicin—hematologic cancer	1.77e-05	0.0101	CbGdCrCtD
Ruxolitinib—PLK1—Epirubicin—Idarubicin—hematologic cancer	1.77e-05	0.0101	CbGdCrCtD
Ruxolitinib—PLK4—Epirubicin—Idarubicin—hematologic cancer	1.77e-05	0.0101	CbGdCrCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	1.74e-05	0.000268	CcSEcCtD
Ruxolitinib—Malnutrition—Methotrexate—hematologic cancer	1.72e-05	0.000265	CcSEcCtD
Ruxolitinib—Haemoglobin—Doxorubicin—hematologic cancer	1.72e-05	0.000265	CcSEcCtD
Ruxolitinib—Headache—Gemcitabine—hematologic cancer	1.72e-05	0.000265	CcSEcCtD
Ruxolitinib—Haemorrhage—Doxorubicin—hematologic cancer	1.72e-05	0.000264	CcSEcCtD
Ruxolitinib—Asthenia—Etoposide—hematologic cancer	1.69e-05	0.000259	CcSEcCtD
Ruxolitinib—Body temperature increased—Triamcinolone—hematologic cancer	1.68e-05	0.000259	CcSEcCtD
Ruxolitinib—Infection—Prednisone—hematologic cancer	1.67e-05	0.000257	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Betamethasone—hematologic cancer	1.67e-05	0.000256	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Dexamethasone—hematologic cancer	1.67e-05	0.000256	CcSEcCtD
Ruxolitinib—Fatigue—Betamethasone—hematologic cancer	1.67e-05	0.000256	CcSEcCtD
Ruxolitinib—Fatigue—Dexamethasone—hematologic cancer	1.67e-05	0.000256	CcSEcCtD
Ruxolitinib—Pruritus—Etoposide—hematologic cancer	1.66e-05	0.000255	CcSEcCtD
Ruxolitinib—Nervous system disorder—Prednisone—hematologic cancer	1.65e-05	0.000254	CcSEcCtD
Ruxolitinib—Skin disorder—Prednisone—hematologic cancer	1.64e-05	0.000251	CcSEcCtD
Ruxolitinib—Malnutrition—Epirubicin—hematologic cancer	1.61e-05	0.000248	CcSEcCtD
Ruxolitinib—PLK1—Cladribine—Clofarabine—hematologic cancer	1.61e-05	0.00919	CbGdCrCtD
Ruxolitinib—Anaemia—Methotrexate—hematologic cancer	1.59e-05	0.000245	CcSEcCtD
Ruxolitinib—Flatulence—Epirubicin—hematologic cancer	1.59e-05	0.000244	CcSEcCtD
Ruxolitinib—PLK4—Teniposide—Etoposide—hematologic cancer	1.56e-05	0.00891	CbGdCrCtD
Ruxolitinib—PLK1—Teniposide—Etoposide—hematologic cancer	1.56e-05	0.00891	CbGdCrCtD
Ruxolitinib—Dizziness—Etoposide—hematologic cancer	1.55e-05	0.000239	CcSEcCtD
Ruxolitinib—Dizziness—Prednisolone—hematologic cancer	1.53e-05	0.000235	CcSEcCtD
Ruxolitinib—Asthenia—Triamcinolone—hematologic cancer	1.53e-05	0.000235	CcSEcCtD
Ruxolitinib—Body temperature increased—Dexamethasone—hematologic cancer	1.53e-05	0.000235	CcSEcCtD
Ruxolitinib—Body temperature increased—Betamethasone—hematologic cancer	1.53e-05	0.000235	CcSEcCtD
Ruxolitinib—PLK1—Cladribine—Nelarabine—hematologic cancer	1.51e-05	0.00864	CbGdCrCtD
Ruxolitinib—Pruritus—Triamcinolone—hematologic cancer	1.51e-05	0.000232	CcSEcCtD
Ruxolitinib—Malnutrition—Doxorubicin—hematologic cancer	1.49e-05	0.000229	CcSEcCtD
Ruxolitinib—Anaemia—Epirubicin—hematologic cancer	1.49e-05	0.000229	CcSEcCtD
Ruxolitinib—Headache—Etoposide—hematologic cancer	1.47e-05	0.000226	CcSEcCtD
Ruxolitinib—Flatulence—Doxorubicin—hematologic cancer	1.47e-05	0.000226	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.46e-05	0.000224	CcSEcCtD
Ruxolitinib—Fatigue—Prednisone—hematologic cancer	1.45e-05	0.000223	CcSEcCtD
Ruxolitinib—Headache—Prednisolone—hematologic cancer	1.45e-05	0.000223	CcSEcCtD
Ruxolitinib—PLK1—Floxuridine—Cladribine—hematologic cancer	1.43e-05	0.0082	CbGdCrCtD
Ruxolitinib—Dizziness—Triamcinolone—hematologic cancer	1.41e-05	0.000217	CcSEcCtD
Ruxolitinib—Infection—Methotrexate—hematologic cancer	1.4e-05	0.000215	CcSEcCtD
Ruxolitinib—PLK1—Clofarabine—Nelarabine—hematologic cancer	1.4e-05	0.00799	CbGdCrCtD
Ruxolitinib—Asthenia—Betamethasone—hematologic cancer	1.39e-05	0.000213	CcSEcCtD
Ruxolitinib—Asthenia—Dexamethasone—hematologic cancer	1.39e-05	0.000213	CcSEcCtD
Ruxolitinib—Nervous system disorder—Methotrexate—hematologic cancer	1.38e-05	0.000212	CcSEcCtD
Ruxolitinib—Anaemia—Doxorubicin—hematologic cancer	1.38e-05	0.000212	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Methotrexate—hematologic cancer	1.38e-05	0.000212	CcSEcCtD
Ruxolitinib—Pruritus—Betamethasone—hematologic cancer	1.37e-05	0.00021	CcSEcCtD
Ruxolitinib—Pruritus—Dexamethasone—hematologic cancer	1.37e-05	0.00021	CcSEcCtD
Ruxolitinib—Skin disorder—Methotrexate—hematologic cancer	1.37e-05	0.00021	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.36e-05	0.00021	CcSEcCtD
Ruxolitinib—Headache—Triamcinolone—hematologic cancer	1.34e-05	0.000205	CcSEcCtD
Ruxolitinib—Body temperature increased—Prednisone—hematologic cancer	1.33e-05	0.000205	CcSEcCtD
Ruxolitinib—Infection—Epirubicin—hematologic cancer	1.31e-05	0.000201	CcSEcCtD
Ruxolitinib—Nervous system disorder—Epirubicin—hematologic cancer	1.29e-05	0.000198	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Epirubicin—hematologic cancer	1.29e-05	0.000198	CcSEcCtD
Ruxolitinib—Skin disorder—Epirubicin—hematologic cancer	1.28e-05	0.000197	CcSEcCtD
Ruxolitinib—Dizziness—Betamethasone—hematologic cancer	1.28e-05	0.000196	CcSEcCtD
Ruxolitinib—Dizziness—Dexamethasone—hematologic cancer	1.28e-05	0.000196	CcSEcCtD
Ruxolitinib—PLK1—Cytarabine—Clofarabine—hematologic cancer	1.26e-05	0.00723	CbGdCrCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.26e-05	0.000194	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.21e-05	0.000187	CcSEcCtD
Ruxolitinib—Fatigue—Methotrexate—hematologic cancer	1.21e-05	0.000186	CcSEcCtD
Ruxolitinib—Headache—Betamethasone—hematologic cancer	1.21e-05	0.000186	CcSEcCtD
Ruxolitinib—Headache—Dexamethasone—hematologic cancer	1.21e-05	0.000186	CcSEcCtD
Ruxolitinib—Infection—Doxorubicin—hematologic cancer	1.21e-05	0.000186	CcSEcCtD
Ruxolitinib—Asthenia—Prednisone—hematologic cancer	1.21e-05	0.000186	CcSEcCtD
Ruxolitinib—Nervous system disorder—Doxorubicin—hematologic cancer	1.2e-05	0.000184	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Doxorubicin—hematologic cancer	1.19e-05	0.000183	CcSEcCtD
Ruxolitinib—Pruritus—Prednisone—hematologic cancer	1.19e-05	0.000183	CcSEcCtD
Ruxolitinib—DYRK1A—Doxorubicin—Epirubicin—hematologic cancer	1.19e-05	0.0068	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Epirubicin—hematologic cancer	1.19e-05	0.0068	CbGdCrCtD
Ruxolitinib—DYRK1A—Idarubicin—Epirubicin—hematologic cancer	1.19e-05	0.0068	CbGdCrCtD
Ruxolitinib—PLK1—Cytarabine—Nelarabine—hematologic cancer	1.19e-05	0.0068	CbGdCrCtD
Ruxolitinib—Skin disorder—Doxorubicin—hematologic cancer	1.18e-05	0.000182	CcSEcCtD
Ruxolitinib—PLK1—Cladribine—Fludarabine—hematologic cancer	1.18e-05	0.00674	CbGdCrCtD
Ruxolitinib—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.14e-05	0.000175	CcSEcCtD
Ruxolitinib—Fatigue—Epirubicin—hematologic cancer	1.14e-05	0.000174	CcSEcCtD
Ruxolitinib—Dizziness—Prednisone—hematologic cancer	1.11e-05	0.000171	CcSEcCtD
Ruxolitinib—Body temperature increased—Methotrexate—hematologic cancer	1.11e-05	0.000171	CcSEcCtD
Ruxolitinib—DYRK1A—Daunorubicin—Doxorubicin—hematologic cancer	1.1e-05	0.00629	CbGdCrCtD
Ruxolitinib—DYRK1A—Epirubicin—Doxorubicin—hematologic cancer	1.1e-05	0.00629	CbGdCrCtD
Ruxolitinib—DYRK1A—Idarubicin—Doxorubicin—hematologic cancer	1.1e-05	0.00629	CbGdCrCtD
Ruxolitinib—PLK1—Clofarabine—Fludarabine—hematologic cancer	1.09e-05	0.00623	CbGdCrCtD
Ruxolitinib—Headache—Prednisone—hematologic cancer	1.05e-05	0.000162	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.05e-05	0.000162	CcSEcCtD
Ruxolitinib—Fatigue—Doxorubicin—hematologic cancer	1.05e-05	0.000161	CcSEcCtD
Ruxolitinib—Body temperature increased—Epirubicin—hematologic cancer	1.04e-05	0.00016	CcSEcCtD
Ruxolitinib—PLK1—Clofarabine—Cytarabine—hematologic cancer	1.03e-05	0.00589	CbGdCrCtD
Ruxolitinib—Asthenia—Methotrexate—hematologic cancer	1.01e-05	0.000155	CcSEcCtD
Ruxolitinib—PLK1—Clofarabine—Cladribine—hematologic cancer	1e-05	0.00574	CbGdCrCtD
Ruxolitinib—Pruritus—Methotrexate—hematologic cancer	9.96e-06	0.000153	CcSEcCtD
Ruxolitinib—Body temperature increased—Doxorubicin—hematologic cancer	9.63e-06	0.000148	CcSEcCtD
Ruxolitinib—PLK1—Gemcitabine—Cytarabine—hematologic cancer	9.54e-06	0.00545	CbGdCrCtD
Ruxolitinib—Asthenia—Epirubicin—hematologic cancer	9.45e-06	0.000145	CcSEcCtD
Ruxolitinib—Pruritus—Epirubicin—hematologic cancer	9.32e-06	0.000143	CcSEcCtD
Ruxolitinib—Dizziness—Methotrexate—hematologic cancer	9.31e-06	0.000143	CcSEcCtD
Ruxolitinib—PLK1—Cytarabine—Fludarabine—hematologic cancer	9.28e-06	0.00531	CbGdCrCtD
Ruxolitinib—Headache—Methotrexate—hematologic cancer	8.82e-06	0.000135	CcSEcCtD
Ruxolitinib—PLK1—Cytarabine—Gemcitabine—hematologic cancer	8.76e-06	0.00501	CbGdCrCtD
Ruxolitinib—Asthenia—Doxorubicin—hematologic cancer	8.74e-06	0.000134	CcSEcCtD
Ruxolitinib—Dizziness—Epirubicin—hematologic cancer	8.71e-06	0.000134	CcSEcCtD
Ruxolitinib—Pruritus—Doxorubicin—hematologic cancer	8.62e-06	0.000132	CcSEcCtD
Ruxolitinib—Headache—Epirubicin—hematologic cancer	8.25e-06	0.000127	CcSEcCtD
Ruxolitinib—PLK1—Daunorubicin—Epirubicin—hematologic cancer	8.12e-06	0.00465	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Epirubicin—hematologic cancer	8.12e-06	0.00465	CbGdCrCtD
Ruxolitinib—PLK1—Doxorubicin—Epirubicin—hematologic cancer	8.12e-06	0.00465	CbGdCrCtD
Ruxolitinib—PLK4—Doxorubicin—Epirubicin—hematologic cancer	8.12e-06	0.00465	CbGdCrCtD
Ruxolitinib—PLK1—Idarubicin—Epirubicin—hematologic cancer	8.12e-06	0.00465	CbGdCrCtD
Ruxolitinib—Dizziness—Doxorubicin—hematologic cancer	8.06e-06	0.000124	CcSEcCtD
Ruxolitinib—Headache—Doxorubicin—hematologic cancer	7.63e-06	0.000117	CcSEcCtD
Ruxolitinib—PLK1—Epirubicin—Doxorubicin—hematologic cancer	7.52e-06	0.0043	CbGdCrCtD
Ruxolitinib—PLK1—Idarubicin—Doxorubicin—hematologic cancer	7.52e-06	0.0043	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Doxorubicin—hematologic cancer	7.52e-06	0.0043	CbGdCrCtD
Ruxolitinib—PLK4—Epirubicin—Doxorubicin—hematologic cancer	7.52e-06	0.0043	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Doxorubicin—hematologic cancer	7.52e-06	0.0043	CbGdCrCtD
Ruxolitinib—ROCK1—Signaling Pathways—VEGFA—hematologic cancer	2.24e-07	2.7e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FN1—hematologic cancer	2.23e-07	2.69e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—PIK3CA—hematologic cancer	2.22e-07	2.68e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MTOR—hematologic cancer	2.22e-07	2.68e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CB—hematologic cancer	2.22e-07	2.68e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—STAT3—hematologic cancer	2.22e-07	2.68e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MDM2—hematologic cancer	2.22e-07	2.67e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NRAS—hematologic cancer	2.21e-07	2.67e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—KRAS—hematologic cancer	2.21e-07	2.67e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MYC—hematologic cancer	2.21e-07	2.67e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—TGFB1—hematologic cancer	2.21e-07	2.66e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—JAK2—hematologic cancer	2.2e-07	2.65e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NFKBIA—hematologic cancer	2.2e-07	2.65e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—BAD—hematologic cancer	2.2e-07	2.65e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CDKN1B—hematologic cancer	2.19e-07	2.64e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CDKN1A—hematologic cancer	2.19e-07	2.64e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PTEN—hematologic cancer	2.18e-07	2.63e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NOTCH1—hematologic cancer	2.18e-07	2.63e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ARNTL—hematologic cancer	2.17e-07	2.62e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL6—hematologic cancer	2.17e-07	2.62e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—AKT1—hematologic cancer	2.16e-07	2.6e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MAPK3—hematologic cancer	2.16e-07	2.6e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CB—hematologic cancer	2.16e-07	2.6e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MTOR—hematologic cancer	2.16e-07	2.6e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MDM2—hematologic cancer	2.15e-07	2.59e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—KRAS—hematologic cancer	2.15e-07	2.59e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAPK8—hematologic cancer	2.14e-07	2.58e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CD80—hematologic cancer	2.14e-07	2.58e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KIT—hematologic cancer	2.13e-07	2.57e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CG—hematologic cancer	2.13e-07	2.57e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—NRAS—hematologic cancer	2.13e-07	2.57e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MAPK3—hematologic cancer	2.12e-07	2.56e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CA9—hematologic cancer	2.11e-07	2.55e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ACP5—hematologic cancer	2.11e-07	2.55e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MYC—hematologic cancer	2.1e-07	2.53e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTPN11—hematologic cancer	2.09e-07	2.53e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PIK3CA—hematologic cancer	2.09e-07	2.52e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TGFB1—hematologic cancer	2.09e-07	2.52e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CB—hematologic cancer	2.09e-07	2.52e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MTOR—hematologic cancer	2.09e-07	2.52e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NCOR2—hematologic cancer	2.09e-07	2.52e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CDKN1B—hematologic cancer	2.08e-07	2.51e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EP300—hematologic cancer	2.08e-07	2.51e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—AKT1—hematologic cancer	2.08e-07	2.5e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PIK3CA—hematologic cancer	2.07e-07	2.49e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MYC—hematologic cancer	2.06e-07	2.49e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HRAS—hematologic cancer	2.06e-07	2.48e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TGFB1—hematologic cancer	2.06e-07	2.48e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—KRAS—hematologic cancer	2.04e-07	2.46e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CASP3—hematologic cancer	2.04e-07	2.46e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—MAPK3—hematologic cancer	2.04e-07	2.46e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL2—hematologic cancer	2.04e-07	2.46e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PIK3CA—hematologic cancer	2.03e-07	2.45e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CREB1—hematologic cancer	2.03e-07	2.45e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—SRC—hematologic cancer	2.03e-07	2.44e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CDKN1B—hematologic cancer	2.02e-07	2.44e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CDKN1A—hematologic cancer	2.02e-07	2.44e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTEN—hematologic cancer	2.02e-07	2.43e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—BRAF—hematologic cancer	2e-07	2.42e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—AKT1—hematologic cancer	2e-07	2.41e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—hematologic cancer	2e-07	2.41e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCND1—hematologic cancer	1.99e-07	2.4e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—IDH1—hematologic cancer	1.99e-07	2.4e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCL2—hematologic cancer	1.99e-07	2.39e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—JUN—hematologic cancer	1.98e-07	2.39e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CASP3—hematologic cancer	1.98e-07	2.39e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6R—hematologic cancer	1.98e-07	2.39e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL2—hematologic cancer	1.98e-07	2.39e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CREBBP—hematologic cancer	1.98e-07	2.38e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PIK3CA—hematologic cancer	1.97e-07	2.38e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL6—hematologic cancer	1.97e-07	2.38e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TXN—hematologic cancer	1.97e-07	2.37e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTO1—hematologic cancer	1.97e-07	2.37e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCC3—hematologic cancer	1.97e-07	2.37e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CDKN1B—hematologic cancer	1.96e-07	2.37e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—STAT3—hematologic cancer	1.95e-07	2.35e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NRAS—hematologic cancer	1.95e-07	2.35e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KRAS—hematologic cancer	1.94e-07	2.34e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HRAS—hematologic cancer	1.94e-07	2.34e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCND1—hematologic cancer	1.93e-07	2.33e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—JUN—hematologic cancer	1.93e-07	2.32e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CDKN1A—hematologic cancer	1.92e-07	2.32e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CASP3—hematologic cancer	1.92e-07	2.32e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SPHK1—hematologic cancer	1.92e-07	2.32e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EP300—hematologic cancer	1.92e-07	2.32e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL2—hematologic cancer	1.92e-07	2.32e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PTEN—hematologic cancer	1.92e-07	2.31e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HRAS—hematologic cancer	1.91e-07	2.31e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KRAS—hematologic cancer	1.91e-07	2.3e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAP2K1—hematologic cancer	1.89e-07	2.27e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HRAS—hematologic cancer	1.88e-07	2.27e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK8—hematologic cancer	1.88e-07	2.26e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PIK3CA—hematologic cancer	1.88e-07	2.26e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CD—hematologic cancer	1.87e-07	2.26e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCND1—hematologic cancer	1.87e-07	2.26e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—SRC—hematologic cancer	1.87e-07	2.25e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—JUN—hematologic cancer	1.87e-07	2.25e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CDKN1A—hematologic cancer	1.87e-07	2.25e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAPK3—hematologic cancer	1.87e-07	2.25e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PTEN—hematologic cancer	1.86e-07	2.25e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—PIK3CA—hematologic cancer	1.86e-07	2.24e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL6—hematologic cancer	1.85e-07	2.24e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—UGT1A1—hematologic cancer	1.85e-07	2.23e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—KRAS—hematologic cancer	1.84e-07	2.21e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL6—hematologic cancer	1.83e-07	2.21e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EP300—hematologic cancer	1.83e-07	2.21e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HRAS—hematologic cancer	1.82e-07	2.2e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK8—hematologic cancer	1.82e-07	2.2e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—AKT1—hematologic cancer	1.82e-07	2.19e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CDKN1A—hematologic cancer	1.81e-07	2.18e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PTEN—hematologic cancer	1.81e-07	2.18e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—STAT3—hematologic cancer	1.8e-07	2.17e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL6—hematologic cancer	1.8e-07	2.17e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NRAS—hematologic cancer	1.8e-07	2.17e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CRABP1—hematologic cancer	1.8e-07	2.17e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC22A1—hematologic cancer	1.8e-07	2.17e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FGF2—hematologic cancer	1.79e-07	2.16e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PIK3CA—hematologic cancer	1.78e-07	2.15e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SRC—hematologic cancer	1.78e-07	2.15e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EP300—hematologic cancer	1.78e-07	2.14e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3R1—hematologic cancer	1.77e-07	2.13e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK8—hematologic cancer	1.77e-07	2.13e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALOX5—hematologic cancer	1.75e-07	2.11e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PIK3CA—hematologic cancer	1.75e-07	2.11e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL6—hematologic cancer	1.75e-07	2.1e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HRAS—hematologic cancer	1.74e-07	2.09e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—hematologic cancer	1.73e-07	2.09e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SRC—hematologic cancer	1.73e-07	2.08e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EP300—hematologic cancer	1.72e-07	2.08e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MAPK3—hematologic cancer	1.72e-07	2.08e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—hematologic cancer	1.72e-07	2.08e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—STAT3—hematologic cancer	1.72e-07	2.07e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NRAS—hematologic cancer	1.71e-07	2.06e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—AKT1—hematologic cancer	1.71e-07	2.06e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NUP98—hematologic cancer	1.7e-07	2.05e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—hematologic cancer	1.69e-07	2.04e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—AKT1—hematologic cancer	1.69e-07	2.04e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PIK3CA—hematologic cancer	1.69e-07	2.03e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—hematologic cancer	1.68e-07	2.03e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MDM2—hematologic cancer	1.68e-07	2.02e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KRAS—hematologic cancer	1.68e-07	2.02e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SRC—hematologic cancer	1.68e-07	2.02e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MYC—hematologic cancer	1.68e-07	2.02e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TGFB1—hematologic cancer	1.67e-07	2.02e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—STAT3—hematologic cancer	1.67e-07	2.01e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NRAS—hematologic cancer	1.66e-07	2e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IL6—hematologic cancer	1.66e-07	2e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—AKT1—hematologic cancer	1.66e-07	2e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HRAS—hematologic cancer	1.65e-07	1.99e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ADCY7—hematologic cancer	1.65e-07	1.99e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NCOA3—hematologic cancer	1.65e-07	1.99e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK3—hematologic cancer	1.64e-07	1.98e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NUP214—hematologic cancer	1.64e-07	1.97e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MTOR—hematologic cancer	1.63e-07	1.97e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CB—hematologic cancer	1.63e-07	1.97e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—hematologic cancer	1.63e-07	1.97e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HRAS—hematologic cancer	1.62e-07	1.95e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—STAT3—hematologic cancer	1.62e-07	1.95e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NRAS—hematologic cancer	1.61e-07	1.94e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—AKT1—hematologic cancer	1.61e-07	1.94e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MTR—hematologic cancer	1.6e-07	1.93e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCG2—hematologic cancer	1.6e-07	1.93e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MYC—hematologic cancer	1.59e-07	1.92e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK3—hematologic cancer	1.59e-07	1.92e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TGFB1—hematologic cancer	1.59e-07	1.92e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL6—hematologic cancer	1.58e-07	1.9e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ENO2—hematologic cancer	1.57e-07	1.89e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HRAS—hematologic cancer	1.56e-07	1.88e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL6—hematologic cancer	1.55e-07	1.87e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MYC—hematologic cancer	1.55e-07	1.87e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KRAS—hematologic cancer	1.55e-07	1.87e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TGFB1—hematologic cancer	1.54e-07	1.86e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK3—hematologic cancer	1.54e-07	1.86e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PIK3CA—hematologic cancer	1.54e-07	1.86e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDKN1B—hematologic cancer	1.53e-07	1.85e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—AKT1—hematologic cancer	1.53e-07	1.85e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTT1—hematologic cancer	1.52e-07	1.84e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—AKT1—hematologic cancer	1.52e-07	1.83e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CASP3—hematologic cancer	1.5e-07	1.81e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MYC—hematologic cancer	1.5e-07	1.81e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL2—hematologic cancer	1.5e-07	1.81e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TGFB1—hematologic cancer	1.5e-07	1.81e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL6—hematologic cancer	1.49e-07	1.8e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SDC1—hematologic cancer	1.49e-07	1.8e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KRAS—hematologic cancer	1.47e-07	1.78e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCND1—hematologic cancer	1.46e-07	1.76e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—JUN—hematologic cancer	1.46e-07	1.76e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—AKT1—hematologic cancer	1.45e-07	1.75e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KRAS—hematologic cancer	1.43e-07	1.72e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—AKT1—hematologic cancer	1.43e-07	1.72e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HRAS—hematologic cancer	1.43e-07	1.72e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CA—hematologic cancer	1.42e-07	1.71e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDKN1A—hematologic cancer	1.42e-07	1.71e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTEN—hematologic cancer	1.41e-07	1.7e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KRAS—hematologic cancer	1.39e-07	1.67e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK8—hematologic cancer	1.38e-07	1.67e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—AKT1—hematologic cancer	1.38e-07	1.66e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6—hematologic cancer	1.36e-07	1.64e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CA—hematologic cancer	1.35e-07	1.63e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EP300—hematologic cancer	1.35e-07	1.62e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HRAS—hematologic cancer	1.32e-07	1.59e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CA—hematologic cancer	1.31e-07	1.58e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—hematologic cancer	1.31e-07	1.58e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SRC—hematologic cancer	1.31e-07	1.58e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—hematologic cancer	1.28e-07	1.54e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CA—hematologic cancer	1.27e-07	1.54e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—hematologic cancer	1.27e-07	1.53e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CD44—hematologic cancer	1.27e-07	1.53e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NQO1—hematologic cancer	1.27e-07	1.53e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—STAT3—hematologic cancer	1.26e-07	1.52e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NRAS—hematologic cancer	1.26e-07	1.52e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6—hematologic cancer	1.26e-07	1.52e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—AKT1—hematologic cancer	1.26e-07	1.52e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HRAS—hematologic cancer	1.25e-07	1.51e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—hematologic cancer	1.23e-07	1.49e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HRAS—hematologic cancer	1.22e-07	1.47e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK3—hematologic cancer	1.21e-07	1.45e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6—hematologic cancer	1.2e-07	1.45e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYCS—hematologic cancer	1.2e-07	1.44e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.19e-07	1.44e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HRAS—hematologic cancer	1.18e-07	1.42e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MYC—hematologic cancer	1.17e-07	1.41e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TGFB1—hematologic cancer	1.17e-07	1.41e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6—hematologic cancer	1.16e-07	1.4e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—AKT1—hematologic cancer	1.16e-07	1.4e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6—hematologic cancer	1.13e-07	1.36e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AKT1—hematologic cancer	1.11e-07	1.33e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KRAS—hematologic cancer	1.08e-07	1.31e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AKT1—hematologic cancer	1.07e-07	1.29e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTP1—hematologic cancer	1.06e-07	1.27e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AKT1—hematologic cancer	1.04e-07	1.26e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCB1—hematologic cancer	1e-07	1.21e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CA—hematologic cancer	9.96e-08	1.2e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NCOR1—hematologic cancer	9.71e-08	1.17e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTM1—hematologic cancer	9.71e-08	1.17e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—hematologic cancer	9.64e-08	1.16e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HRAS—hematologic cancer	9.22e-08	1.11e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6—hematologic cancer	8.82e-08	1.06e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MTHFR—hematologic cancer	8.58e-08	1.03e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT1—hematologic cancer	8.14e-08	9.81e-07	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CG—hematologic cancer	7.21e-08	8.69e-07	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CREBBP—hematologic cancer	6.68e-08	8.06e-07	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CD—hematologic cancer	6.34e-08	7.64e-07	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALB—hematologic cancer	6.25e-08	7.54e-07	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3R1—hematologic cancer	5.98e-08	7.21e-07	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CB—hematologic cancer	5.52e-08	6.66e-07	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTEN—hematologic cancer	4.77e-08	5.75e-07	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—EP300—hematologic cancer	4.55e-08	5.49e-07	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CA—hematologic cancer	3.37e-08	4.06e-07	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKT1—hematologic cancer	2.75e-08	3.32e-07	CbGpPWpGaD
